Delcath Systems, Inc. - pr0900008-3

The Delcath System™, or Percutaneous Hepatic Perfusion (PHP)™, offers a new regionalized approach for the treatment of unresectable hepatic malignancies in which the drug Melphalan is administered via the hepatic artery and the venous effluent of the liver is collected and filtered using a percutaneously placed catheter and filtration system. The treatment is investigational, but observed benefits of the procedure include:

Minimally invasive – PHP™ utilizes a series of catheters and extracorporeal filters to infuse high doses of chemotherapeutic agents to tumors in the liver with minimal systemic exposure.

Higher Dosing – PHP™ allows infusion doses exceeding those of systemic or intra-arterial administration.

Treatment Flexibility - PHP™ can be performed in an operating room or in a radiology suite under local or general anesthesia.

Repeatable Procedure - Unlike surgical isolated hepatic perfusion (IHP), which can be performed only once, PHP™ can be repeated several times. Patients within the trial usually receive the treatment at four-week intervals and up to ten treatments have been administered to a patient.

Decreased Toxicity - Filtration of the hepatic venous effluent can reduce systemic exposure of chemotherapy by 80% to 90% compared to hepatic artery infusion alone.